Shanghai Henlius Biotech Inc
HKEX:2696
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
11.7
23.2
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Shanghai Henlius Biotech Inc
Selling, General & Administrative
Shanghai Henlius Biotech Inc
Selling, General & Administrative Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Shanghai Henlius Biotech Inc
HKEX:2696
|
Selling, General & Administrative
-¥2.2B
|
CAGR 3-Years
-71%
|
CAGR 5-Years
-82%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Selling, General & Administrative
-¥10.9B
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Selling, General & Administrative
-¥1.9B
|
CAGR 3-Years
-32%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
N/A
|
|
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Selling, General & Administrative
-¥781.3m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-17%
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Selling, General & Administrative
-¥3.5B
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
-28%
|
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Selling, General & Administrative
-¥397.2m
|
CAGR 3-Years
-51%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
|
Shanghai Henlius Biotech Inc
Glance View
Shanghai Henlius Biotech, Inc. engages in the development and production of monoclonal antibody drugs. The company is headquartered in Shanghai, Shanghai and currently employs 2,234 full-time employees. The company went IPO on 2019-09-25. The Company’s main products include rituximab injection HLX01 (Hanlikang), Herceptin (trastuzumab) biosimilar HLX02, Humira (adalimumab) biosimilar HLX03 and Avastin (bevacizumab) biosimilar HLX04, as well as bio-innovative drug candidates, including HLX06 (a novel VEGFR2 inhibitor), HLX07 (an EGFR inhibitor), HLX10 (a novel PD-1 inhibitor), HLX20 (a novel PD-L1 inhibitor) and HLX22 (a novel HER2 inhibitor), among others. The firm is also engaged in the provision of related technical services. The firm operates its businesses primarily in Mainland China and the United States.
See Also
What is Shanghai Henlius Biotech Inc's Selling, General & Administrative?
Selling, General & Administrative
-2.2B
CNY
Based on the financial report for Dec 31, 2023, Shanghai Henlius Biotech Inc's Selling, General & Administrative amounts to -2.2B CNY.
What is Shanghai Henlius Biotech Inc's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 5Y
-82%
Over the last year, the Selling, General & Administrative growth was -54%. The average annual Selling, General & Administrative growth rates for Shanghai Henlius Biotech Inc have been -71% over the past three years , -82% over the past five years .
You don't have any saved screeners yet
